Patients with limited-stage small cell lung cancer reported better quality of life and less perceived inconvenience at three weeks when treated with once-daily higher-dose thoracic radiotherapy compared with standard twice-daily regimens, according to clinical trial data presented at the American Society of Clinical Oncology Annual Meeting.
Trial Design and Quality-of-Life Findings at Three Weeks
The findings stem from the CALGB-70702 trial, a planned substudy of the CALGB 30610 study. Researchers examined patient-reported outcomes to help guide clinical decision-making after the main trial demonstrated that 70-Gray once-daily thoracic radiotherapy did not achieve superior overall survival compared with the standard 45-Gray twice-daily regimen in limited-stage small cell lung cancer.
Presenter Apar Kishor Ganti, MD, of the University of Nebraska Medical Center in Omaha, reported that patients receiving the once-daily regimen experienced significantly lower mean worsening on total functional assessment scores at week 3. Acute esophagitis scores and difficulty swallowing were also significantly greater in the twice-daily arm at that same early time point.
Shifting Scores Across the 12-Week Timeline
While the once-daily arm showed advantages early on, the trajectory shifted over the course of recovery. By week 12, quality-of-life measures told a different story. The mean worsening on lung cancer trial outcome indexes was significantly greater in the once-daily group than in the twice-daily arm.
Study discussant Kristin Ann Higgins, MD, of Emory University’s Winship Cancer Institute in Atlanta, explained that the acute side effect peak at week 3 for the twice-daily arm simply coincided with the conclusion of that shorter treatment course. Because once-daily radiation runs over a longer schedule, a comparable dip in quality of life occurs later in the timeline.
Dr. Higgins added that quality of life differs for the different fractionation regimens, and the interpretation depends heavily on the specific week investigators choose to analyze.
Weighing Convenience Against Long-Term Toxicity
Beyond questionnaires and symptom scores, patient perception of daily routine played a measurable role in how these therapies are evaluated. Consent was obtained from 417 patients for the substudy, which maintained an 87 percent questionnaire completion rate at baseline and a 71 percent rate at week 52.
When asked about the burden of treatment, one-quarter of patients in the once-daily arm felt the schedule was inconvenient. That figure rose to one-third among patients undergoing the standard twice-daily regimen. Dr. Ganti observed that the once-a-day arm was considered to be less inconvenient by most patients and will likely shape future clinical practice.
However, Joe Y. Chang, MD, PhD, of the MD Anderson Cancer Center at the University of Texas in Houston, noted the practical complexity of labeling either option a reduced schedule. One regimen requires twice-daily sessions over three weeks, while the other spans seven weeks of daily visits. In his view, acute toxicities alone do not provide a definitive dividing line for clinicians.
“Other factors, including long-term toxicity, could play more of a role in this setting.”
Joe Y. Chang, MD, PhD, MD Anderson Cancer Center at the University of Texas in Houston
